|1.||Bigner, Darell D: 30 articles (06/2015 - 01/2002)|
|2.||Sampson, John H: 28 articles (06/2015 - 01/2002)|
|3.||Cavenee, Webster K: 23 articles (07/2015 - 03/2002)|
|4.||Archer, Gary E: 17 articles (06/2015 - 01/2002)|
|5.||Mischel, Paul S: 15 articles (07/2015 - 09/2002)|
|6.||Heimberger, Amy B: 15 articles (06/2015 - 01/2002)|
|7.||Herndon, James E: 14 articles (02/2014 - 01/2008)|
|8.||Johns, Terrance G: 14 articles (11/2013 - 03/2002)|
|9.||Cloughesy, Timothy F: 13 articles (07/2015 - 09/2002)|
|10.||Scott, Andrew M: 13 articles (05/2015 - 03/2002)|
11/01/1995 - "In addition, the tumor-specific nature of EGFRvIII combined with improved knowledge of immune mechanisms, especially in the context of the central nervous system, will facilitate the design of highly selective cell-mediated therapeutic approaches with a view toward obtaining tumor-specific immunity."
10/01/2011 - "These observations confirm the immunotherapeutic potential of antibody combinations against EGFR, and demonstrate that tumor selectivity can be improved by combining therapeutic EGFR mAb with an antibody against EGFRvIII."
01/01/2007 - "Anti-cancer treatments directed at the EGFRvIII should be equally effective in men from both subpopulations."
06/01/2015 - "EGFRvIII was eliminated in 4/6 (67%) tumor samples obtained after >3 months of therapy. "
06/15/2012 - "Targeting of the epitope for mAb806 also appears to be an improved strategy to inhibit tumors that express EGFRvIII. "
04/01/2007 - "In conclusion, EGFR-retargeted measles virus strains have comparable therapeutic efficacy to the unmodified virus in glioma cells overexpressing EGFR or EGFRvIII in vivo and in vitro, and improved therapeutic index, a finding with potential translational implications in glioma virotherapy."
09/01/2013 - "The efficacy of sLrig1 and the affected downstream signaling was studied in vitro and in vivo in glioma cells displaying variable expression of wild-type and/or a constitutively active EGFR mutant (EGFRvIII). "
01/02/2015 - "Thus, our study suggests that ligand in the milieu of EGFRvIII-expressing GBM cells is likely to influence the EGFRvIII-Met interaction and resistance to treatment, and highlights a novel antagonistic interaction between EGFRwt and EGFRvIII in glioma cells. "
06/15/2006 - "For in vivo studies, F98 wild-type receptor-negative or EGFRvIII human gene-transfected receptor-positive F98(npEGFRvIII) glioma cells were implanted i.c. "
01/15/2006 - "Thus, our study provides a new insight into oncogenic signaling by EGFRvIII and improves our understanding of how autocrine loops are generated in glioma."
|3.||Glioblastoma (Glioblastoma Multiforme)
02/18/2015 - "On the basis of these results, we have designed a phase 1 clinical study of CAR T cells transduced with humanized scFv directed to EGFRvIII in patients with either residual or recurrent glioblastoma (NCT02209376). "
05/15/2014 - "Data from phase II EGFRvIII-targeted vaccination trials compare favorably with the present contemporary results, supporting the further exploration of EGVRvIII vaccination in newly diagnosed glioblastoma."
09/01/2013 - "Recent studies have identified iNOS as a critical regulator of glial transformation downstream of EGFRvIII/STAT3 signaling, a key oncogenic pathway in glioblastoma. "
12/20/2005 - "In the present study, the effects of PTEN on cell invasion were investigated in U87DeltaEGFR glioblastoma cells with EGFRvIII expression but missing PTEN. "
02/15/2005 - "In our study of glioblastoma multiforme patients, 46% (n = 91) failed to express EGFR, 54% (n = 105) had overexpression of the wild-type EGFR, and 31% (n = 61) also expressed the EGFRvIII. "
|4.||Brain Neoplasms (Brain Tumor)
06/15/2006 - "These data convincingly show the therapeutic efficacy of molecular targeting of EGFRvIII using either boronated monoclonal antibody L8A4 alone or in combination with BPA and should provide a platform for the future development of combinations of high and low molecular weight delivery agents for BNCT of brain tumors."
01/01/2005 - "Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4."
11/14/2014 - "Since TF is upregulated by oncogenic mutations occurring in different subsets of human brain tumors we investigated whether TF contributes to tumourigenesis driven by oncogenic activation of EGFR (EGFRvIII) and RAS pathways in the brain. "
02/15/2014 - "At elevated doses, infusion with EGFRvIII mCAR T cells led to cures in all mice with brain tumors. "
01/01/2014 - "Importantly, these results endorse clinical translation of this CAR in patients with EGFRvIII-expressing brain tumors. "
|5.||Lung Neoplasms (Lung Cancer)
09/01/2009 - "Four novel mutations (E709K, V765G, Ins770G, and G1022S) and one mutation well-known in lung cancer (L858R) were identified in six HNSCC samples (7%), but we could not find any mutations in the extracellular domain of EGFR, such as EGFRvIII, in this study. "
02/01/2007 - "Further studies are needed to confirm the mechanisms of EGFRvIII mutations for possible anti-EGFR therapy for lung cancer."
02/01/2007 - "We genotyped the EGFRvIII mutation status in 252 surgically treated lung cancer cases. "
02/01/2007 - "EGFRvIII mutation in lung cancer correlates with increased EGFR copy number."
01/01/2003 - "Because the cell-specific expression of EGFRvIII in lung has not been well documented, we examined the expression of EGFRvIII in 76 non-small cell lung cancers (NSCLCs) and 10 non-neoplastic lung tissues by immunohistochemistry using a new monoclonal antibody specific for this variant receptor. "
|2.||Epidermal Growth Factor Receptor (EGF Receptor)
|4.||erlotinib (CP 358,774)
|7.||Antigen Receptors (Antigen Receptor)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)
|4.||Boron Neutron Capture Therapy